Jamie Dananberg
Chief Tech/Sci/R&D Officer bij ANNEXON, INC.
Vermogen: 371 606 $ op 31-03-2024
Profiel
Jamie Dananberg is currently the Chief Medical Officer at Annexon, Inc. and a Trustee at Keck Graduate Institute of Applied Life Sciences.
Previously, he worked as the VP-Translational Medicine & Tailored Therapeutics at Eli Lilly & Co. from 2000 to 2012, as the Executive Vice President at Takeda Pharmaceutical Co., Ltd.
from 2012 to 2015, and as the Chief Medical Officer at Unity Biotechnology, Inc. from 2016 to 2023.
He received his undergraduate and doctorate degrees from Tufts University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ANNEXON, INC.
0.04% | 16-02-2024 | 39 000 ( 0.04% ) | 279 630 $ | 31-03-2024 |
| 24-04-2023 | 56 083 ( 0.33% ) | 91 976 $ | 31-03-2024 |
Actieve functies van Jamie Dananberg
| Bedrijven | Functie | Begin |
|---|---|---|
| ANNEXON, INC. | Chief Tech/Sci/R&D Officer | 27-07-2023 |
| Keck Graduate Institute of Applied Life Sciences | Director/Board Member | - |
Eerdere bekende functies van Jamie Dananberg
| Bedrijven | Functie | Einde |
|---|---|---|
| UNITY BIOTECHNOLOGY, INC. | Chief Tech/Sci/R&D Officer | 30-04-2023 |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Corporate Officer/Principal | 01-10-2015 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01-09-2012 |
Opleiding van Jamie Dananberg
| Tufts University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| ANNEXON, INC. | Health Technology |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
| UNITY BIOTECHNOLOGY, INC. | Health Technology |
